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ABSTRACT 
 
TO STUDY THE EFFICACY OF ORMELOXIFENE IN THE 
MEDICAL MANAGEMENT OF ABNORMAL UTERINE 
BLEEDING (AUB). 
 
OBJECTIVES: 
1) To evaluate the efficacy of ormeloxifene for abnormal uterine bleeding. 
2) To study the acceptability of ormeloxifene. 
3) To study the adverse effects of ormeloxifene used for abnormal uterine bleeding. 
4) To study the recurrence of heavy menstrual bleeding in patients treated with 
ormeloxifene. 
 
METHODS: 
 About 100 patients attending the gynaec opd  at Institute of obstetrics and 
gynaecology Kasturba Gandhi Hospital  and Institute of Obstetrics and Gynaecology with 
complaints of heavy menstrual bleeding were included.Basic haemoglobin levels and 
platelet count was performed.Endometrial thickness by transvaginal ultrasonography and 
pictorial blood loss assessment chart scoring were studied. 
 
INCLUSION CRITERIA : 
 Patients presenting with abnormal uterine bleeding were recruited for study after 
detailed gynecological examinations and investigations to rule out any uterine pathology , 
congenital malformation and other organic causes for AUB.  
 
EXCLUSION CRITERIA : 
1.Leiomyoma 
2. Endometriosis 
3. Malignancies of genital tract 
 4. Liver dysfunction  
5. Heart disease 
6. Coagulopathies 
  
7. Renal disease 
8. Pregnancy 
9. IUCD /oral pill users 
10. Lactating women in the first 6 months of postnatal period 
 11. Thyroid disorder 
12. History of abortion within last 3 months 
13. Hypersensitivity to drug  
 
 Patients meeting the inclusion criteria were given a trial ormeloxifene 60mg twice a 
week for 12 weeks and the above parameters were reviewed after a period of 3 months. 
Ormeloxifene 60mg once a week for 12 weeks and the same parameters were assessed. 
The repeated measures anova statistical tool was used to find the difference in three period. 
SPSS 20 version was used. 
 
RESULTS: 
 In this study about 100 patients were recruited after meeting the inclusion and 
exclusion criteria. The mean PBAC score, significantly reduced from 206.8788 to 94.4545 
at the end of 3 months and further reduced to 77.9596 at the end of 6 months.( p <0.0001 
significant ). On treatment with ormiloxifene , Hb increased by 1.38gm% ( mean Hb of 
8.5470 gm% to 9.3800 gm% ) at the end of 3 months and further improved by 0.547gm % ( 
9.300 gm% to 9.927gm% ) at the end of 6 months.  
 
 The mean endometrial thickness reduced from 11.0670 mm to 10.1034 mm at the 
end of 3 months and further reduced to 8.9560 mm at the end of 6 months(p < 0 .05) . So 
there was significant reduction in endometrial thickness, PBAC score in patients treated 
with ormiloxifene along with considerable improvement in Hb level thereby improving the 
quality of life of patients with AUB.   
 
 Out of these women about 4 % of women turned up to gynaecology op with recurrent 
heavy menstrual bleeding , who opted for trial with LNG-IUD . So ormiloxifene is cost 
effective drug in the medical management of AUB with few side effects like 
hypomenorrhoea , amenorrhoea , headache , nausea and with low recurrence rates . In 
developing country like India medical management with ormiloxifene can be a safer option 
  
thereby reducing the financial burden by limiting the number of hysterectomies and the 
morbidities associated with surgery.  
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